News
February 15, 2019
Encouraging New Research for People with Lupus Nephritis
Lupus nephritis (LN) most often develops within the first five years after the symptoms of lupus start, and usually affects people between 20 and 40 years of age. LN is a major risk factor for overall mortality and morbidity in systemic lupus erythematosus (SLE). Researchers analyzed the renal response rates of close to 100 people with LN after induction therapy and found that monitoring and measurement of three key factors resulted in better renal outcomes. The findings are encouraging and may guide future research into renal outcome prediction and renal flare prevention in people with proliferative and membranous LN. Learn about how lupus affects the renal (kidney) system.
See More:
The latest from Inside Lupus Research
News
UPDATE: Gazyva® Shows Superiority Over Standard Therapy for People with Active Lupus Nephritis
News
UPDATE: Investigational CAR-T Cell Therapy ADI-001 Receives FDA Fast Track Designation for Refractory Systemic Lupus Erythematosus with Extrarenal Involvement
News
New Study Finds Racial and Gender-Specific Approaches May Boost Black Participation in Lupus Clinical Trials
News
Allogene Therapeutics’ ALLO-329 Received FDA IND Clearance for Autoimmune Disease Trial